Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 195

  • Filters activated: Cancer. Clear all to show 245 items.
1.

The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy.

Lv Y, Li B, Han K, Xiao Y, Yu X, Ma Y, Jiao Z, Gao J.

Korean J Physiol Pharmacol. 2018 Nov;22(6):617-625. doi: 10.4196/kjpp.2018.22.6.617. Epub 2018 Oct 25.

2.

Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment.

Filippova N, Yang X, An Z, Nabors LB, Pereboeva L.

J Cancer Sci Ther. 2018;10(8):190-197. doi: 10.4172/1948-5956.1000543. Epub 2018 Aug 6.

3.

The Nedd8-activating enzyme inhibitor MLN4924 (TAK-924/Pevonedistat) induces apoptosis via c-Myc-Noxa axis in head and neck squamous cell carcinoma.

Zhang W, Liang Y, Li L, Wang X, Yan Z, Dong C, Zeng MS, Zhong Q, Liu XK, Yu J, Sun S, Liu X, Kang J, Zhao H, Jeong LS, Zhang Y, Jia L.

Cell Prolif. 2018 Oct 19:e12536. doi: 10.1111/cpr.12536. [Epub ahead of print]

PMID:
30341788
4.

[Incorporation of novel agents into the treatment for acute myeloid leukemia].

Yamauchi T.

Rinsho Ketsueki. 2018;59(10):1988-1996. doi: 10.11406/rinketsu.59.1988. Japanese.

PMID:
30305501
5.

Leveraging Hypomethylating Agents for Better MDS Therapy.

Bradley TJ, Watts JM, Swords RT.

Curr Hematol Malig Rep. 2018 Sep 28. doi: 10.1007/s11899-018-0477-3. [Epub ahead of print] Review.

PMID:
30267380
6.

AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.

Chen X, Cui D, Bi Y, Shu J, Xiong X, Zhao Y.

Cell Cycle. 2018;17(16):2069-2079. doi: 10.1080/15384101.2018.1515550. Epub 2018 Sep 19.

PMID:
30198810
7.

Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.

Assumpção ALFV, Lu Z, Marlowe KW, Shaffer KS, Pan X.

Vet Comp Oncol. 2018 Dec;16(4):606-615. doi: 10.1111/vco.12428. Epub 2018 Aug 13.

PMID:
30101447
8.

Neddylation, a novel paradigm in liver cancer.

Delgado TC, Barbier-Torres L, Zubiete-Franco I, Lopitz-Otsoa F, Varela-Rey M, Fernández-Ramos D, Martínez-Chantar ML.

Transl Gastroenterol Hepatol. 2018 Jun 30;3:37. doi: 10.21037/tgh.2018.06.05. eCollection 2018. Review.

9.

Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation.

Liu M, Jiang K, Lin G, Liu P, Yan Y, Ye T, Yao G, Barr MP, Liang D, Wang Y, Gong P, Meng S, Piao H.

J Exp Clin Cancer Res. 2018 Jul 24;37(1):165. doi: 10.1186/s13046-018-0806-3.

10.

Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.

Olaverria Salavaggione GN, Duggan MC, Carson WE.

Melanoma Res. 2018 Oct;28(5):390-397. doi: 10.1097/CMR.0000000000000474.

PMID:
30020196
11.

CRL4DCAF2 negatively regulates IL-23 production in dendritic cells and limits the development of psoriasis.

Huang T, Gao Z, Zhang Y, Fan K, Wang F, Li Y, Zhong J, Fan HY, Cao Q, Zhou J, Xiao Y, Hu H, Jin J.

J Exp Med. 2018 Aug 6;215(8):1999-2017. doi: 10.1084/jem.20180210. Epub 2018 Jul 17.

PMID:
30018073
12.

UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.

Zhou W, Xu J, Tan M, Li H, Li H, Wei W, Sun Y.

Mol Cell. 2018 Jun 21;70(6):1008-1024.e6. doi: 10.1016/j.molcel.2018.06.002.

PMID:
29932898
13.

Inhibition of CRL-NEDD8 pathway as a new approach to enhance ATRA-induced differentiation of acute promyelocytic leukemia cells.

Liu S, Wan J, Kong Y, Zhang Y, Wan L, Zhang Z.

Int J Med Sci. 2018 Apr 3;15(7):674-681. doi: 10.7150/ijms.23782. eCollection 2018.

14.

MLN4924 suppresses lipopolysaccharide-induced proinflammatory cytokine production in neutrophils in a dose-dependent manner.

Jin J, Jing Z, Ye Z, Guo L, Hua L, Wang Q, Wang J, Cheng Q, Zhang J, Xu Y, Wei L.

Oncol Lett. 2018 May;15(5):8039-8045. doi: 10.3892/ol.2018.8333. Epub 2018 Mar 23.

15.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A.

Invest New Drugs. 2018 May 21. doi: 10.1007/s10637-018-0610-0. [Epub ahead of print]

PMID:
29781056
16.

A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.

Xu B, Deng Y, Bi R, Guo H, Shu C, Shah NK, Chang J, Liu G, Du Y, Wei W, Wang C.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093. doi: 10.1007/s00280-018-3582-z. Epub 2018 Apr 17.

PMID:
29667067
17.

Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.

Zheng S, Leclerc GM, Li B, Swords RT, Barredo JC.

Oncotarget. 2017 Dec 31;9(5):5529-5544. doi: 10.18632/oncotarget.23797. eCollection 2018 Jan 19.

18.

The SKP1-Cullin-F-box E3 ligase βTrCP and CDK2 cooperate to control STIL abundance and centriole number.

Arquint C, Cubizolles F, Morand A, Schmidt A, Nigg EA.

Open Biol. 2018 Feb;8(2). pii: 170253. doi: 10.1098/rsob.170253.

19.

Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin.

Lin S, Shang Z, Li S, Gao P, Zhang Y, Hou S, Qin P, Dong Z, Hu T, Chen P.

Oncol Lett. 2018 Feb;15(2):2583-2589. doi: 10.3892/ol.2017.7616. Epub 2017 Dec 14.

20.

MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells.

Xu Q, Lin G, Xu H, Hu L, Wang Y, Du S, Deng W, Hu W, Cheng W, Jiang K.

Oncol Lett. 2018 Jan;15(1):515-521. doi: 10.3892/ol.2017.7314. Epub 2017 Nov 1.

Supplemental Content

Loading ...
Support Center